PRESS RELEASE

01.29.2014

Epic Sciences partners with LabCorp to accelerate European clinical sample processing CTC technology.

LinkedIn
Twitter
Follow by Email

Agreement provides important access point to meet global demand for Epic’s Technology.

Epic Sciences (Epic) announced today an agreement with Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH) to expedite sample processing for Epic’s circulating tumor cell (CTC) technology to support European clinical trials. For Epic’s clinical trial partners and customers, LabCorp’s Central Laboratory in Mechelen, Belgium is able to quickly process samples, which will then be sent to Epic’s GLP certified laboratory in La Jolla, CA for downstream detection and molecular characterization of CTCs.

“To meet the global demand for Epic’s circulating tumor cell technology, this partnership with LabCorp will provide an important access point for all European and Middle Eastern clinical trials sample processing, deposition and banking,” said Murali Prahalad, Ph.D., president and CEO of Epic Sciences. “Working with LabCorp, we have been able to rapidly validate our technology and expand our clinical trial services to Europe for our pharma partners and clinical trial customers.”

“We are impressed with the diligence and thoroughness of the Epic team and how Epic’s circulating tumor cell technology has swiftly matured to meet LabCorp’s quality standards for process and reproducibility,” said Dr. Steven M. Anderson, senior vice president and global head of clinical trials of LabCorp. “The ability to detect, quantitate and molecularly characterize circulating tumor cells will provide significant, actionable information in support of oncology clinical trials.”

Circulating tumor cells (CTCs) are released from solid tumors and enter the bloodstream. Epic’s CTC technology can isolate, count and characterize CTCs from a blood sample to provide an alternate way to identify appropriate patients for clinical trials, select optimal therapeutics given a particular cancer sub-type and understand treatment effectiveness, disease progression and metastatic risk. Epic is currently involved in 27 individual oncology clinical trials occurring around the world and is collaborating with its partners to create companion diagnostic products for oncology drug candidates. Epic’s mission is to provide a better way to monitor and personalize cancer treatments.

About Epic Sciences

At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.

We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.

For more information, visit epicsciences.com.

Stay in touch on LinkedIn, on Twitter@EpicSciences and Facebook.com/EpicSciences.

Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,+1.858.344.8091